BMS beats estimates on Eliquis and Opdivo strength

2 February 2023
bristol-myers-squibb_large

US drugmaker Bristol Myers Squibb (NYSE: BMY) was trading 2% higher at lunchtime Thursday after presenting its fourth quarter and full year 2022 financial results.

The company’s adjusted earnings per share (EPS) for the fourth quarter of 2022 came in at $1.82. This was 1% down on the same period of 2021, but well ahead of the FactSet consensus of $1.73.

"Well-positioned for multiple waves of innovation"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical